Evidence map›Paper›PMID 36258058›Full record

ArticleAnnals of surgical oncology2023

The Cancer Hub Approach for Upper Gastrointestinal Surgery During COVID-19 Pandemic: Outcomes from a UK Cancer Centre.

Joseph P Doyle, Pranav H Patel, Sophie L F Doran, Long R Jiao, David Cunningham, David Nicol, Vasileios K Mavroeidis, William H Allum, Asif M Chaudry, Ricky H Bhogal and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Annals of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. The Pancreas in Coronavirus Disease 2019 Infection.Gastroenterology clinics of North America · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Joseph P DoyleDepartment of Surgery, The Royal Marsden Hospital, London, UK.
Pranav H PatelDepartment of Surgery, The Royal Marsden Hospital, London, UK.
Sophie L F DoranDepartment of Surgery, The Royal Marsden Hospital, London, UK.
Long R JiaoDepartment of Surgery, The Royal Marsden Hospital, London, UK.
David CunninghamGI Unit, The Royal Marsden Hospital, London, UK.
David NicolDepartment of Surgery, The Royal Marsden Hospital, London, UK.
Vasileios K MavroeidisDepartment of Surgery, The Royal Marsden Hospital, London, UK.
William H AllumDepartment of Surgery, The Royal Marsden Hospital, London, UK.
Asif M ChaudryDepartment of Surgery, The Royal Marsden Hospital, London, UK.
Ricky H Bhogal *Department of Surgery, The Royal Marsden Hospital, London, UK.
Sacheen Kumar *Department of Surgery, The Royal Marsden Hospital, London, UK. sacheen.kumar@rmh.nhs.uk.
Royal Marsden Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe coronavirus disease 2019 (COVID-19) pandemic caused unprecedented disruption to global healthcare delivery. In England, the majority of elective surgery was postponed or cancelled to increase intensive care capacity. Our unit instituted the 'RM Partners Cancer Hub' at the Royal Marsden Hospital in London, to deliver ongoing cancer surgery in a 'COVID-lite' setting. This article describes the operational set-up and outcomes for upper gastrointestinal (UGI) cancer resections performed during this period.

methodsFrom April 2020 to April 2021, the Royal Marsden Hospital formed the RM Partners Cancer Hub. This approach was designed to coordinate resources and provide as much oncological treatment as feasible for patients across the RM Partners West London Cancer Alliance. A UGI surgical case prioritisation strategy, along with strict infection control pathways and pre-operative screening protocols, was adopted.

resultsA total of 231 patients underwent surgery for confirmed or suspected UGI cancer during the RM Partners Cancer Hub, with 213 completed resections and combined 90-day mortality rate of 3.5%. Good short-term survival outcomes were demonstrated with 2-year disease free survival (DFS) and overall survival (OS) for oesophageal (70.8% and 72.9%), gastric (66.7% and 83.3%) and pancreatic cancer resections (68.0% and 88.0%). One patient who developed perioperative COVID-19 during the RM Partners Cancer Hub operation made a full recovery with no lasting clinical sequelae.

conclusionOur experience demonstrates that the RM Partners Cancer Hub approach is a safe strategy for continuing upper gastrointestinal (GI) resectional surgery during future periods of healthcare service disruption.

Indexed as

COVID-19Digestive System Surgical ProceduresNeoplasmsHumansPandemicsUnited Kingdom

Identifiers

PMID36258058
PMCPMC9579643
OpenAlexW4306739698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.